nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2021-25-2-27-34nefr-1940Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESДигидропиридиновые блокаторы кальциевых каналов для нефропротективной терапии гипертензивных больных с хронической болезнью почекDihydropyridine calcium channel blockers for the renoprotective therapy of hypertensive patients with chronic kidney diseasehttps://orcid.org/0000-0003-3730-3665КузьминО. Б.KuzminO. B.

Проф. Кузьмин Олег Борисович, д-р мед. наук

460000, Россия, г. Оренбург, Парковый пр., д. 7

Тел.: (8) 9198487679

Prof. Oleg B. Kuzmin, MD, PhD, DMedSci

460000, Russia, Orenburg, Park. av., 7

Phone: (8) 9198487679

kuzmin.orgma@mail.ruЖежаВ. В.ZhezhaV. V.

Жежа Владислав Викторович, канд. мед. наук

460000, Россия, г. Оренбург, Парковый пр., д. 7

Тел.: (8) 9510385128

Vladislav V. Zhezha, MD, PhD

460000, Russia, Orenburg, Park. av., 7

Phone: (8) 9510385128

zhezha56@mail.ruhttps://orcid.org/0000-0002-1981-179XБелянинВ. В.BelyaninV. V.

Белянин Виталий Васильевич канд мед наук

46000, Россия, Оренбург, Парковый пр., д. 7

Тел.: (8) 9878703415

Vitaliy V. Belyanin, MD, PhD

460000, Russia, Orenburg, Park. av., 7

Phone: (8) 9128442604

Vitbelya@yandex.ruКафедра фармакологии Оренбургского государственного медицинского университетаРоссияDepartament of pharmacology Orenburg State Medical UniversityRussian Federation2021120220212522734Copyright © Кузьмин О.Б., Жежа В.В., Белянин В.В., 20212021Кузьмин О.Б., Жежа В.В., Белянин В.В.Kuzmin O.B., Zhezha V.V., Belyanin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1940

Амлодипин и селективные дигидропиридиновые блокаторы L-Са2+-каналов второго поколения при добавлении к ингибиторам АПФ или заменяющим их антагонистам АТ1-ангиотензиновых рецепторов не улучшают клинические почечные исходы у гипертензивных больных с хронической болезнью почек. Эти препараты не устраняют внутриклубочковую гипертензию, лежащую в основе гипертонической нефропатии, и могут оказывать неблагоприятное влияние на нейрогормональный статус организма, вызывая активацию симпатической и ренин-ангиотензин-альдостероновой систем. В обзоре представлены результаты клинических исследований, посвященных оценке эффективности применения в этой популяции пациентов нового дигидропиридинового блокатора L-Са2+-каналов третьего поколения лерканидипина, двойного блокатора T/L-Са2+-каналов бенедипина и двойного блокатора N/L-Са2+-каналов цилнидипина, отличающихся от своих предшественников выраженными нефропротективными свойствами.

Amlodipine and selective dihydropyridine Ca2+ channels blockers of the second generation in addition to ACE inhibitors or replacing them antagonists of AT1-angiotensin receptors don’t improve clinical renal outcomes in hypertensive patients with chronic kidney disease. These drugs don’t eliminate intraglomerular hypertension that underlies hypertensive nephropathy and can have an adverse effect on the neurohormonal status of the organism, triggering the activation of the sympathetic and renin-angiotensin-aldosterone systems. The review presents the results of clinical studies evaluating the effectiveness of the use in this patients population of a new dihydropyridine blocker L-Ca2+ channels third-generation lercanidipine, dual blocker T/L-Ca2+ channels benedipine and dual blocker N/L-Ca2+ channels cilnidipine, that differ from their predecessors expressed renoprotective properties.

артериальная гипертензияхроническая болезнь почекдигидропиридиновые блокаторы L-T/L-N/L-Са2+-каналовarterial hypertensionchronic kidney diseasedihydropyridine blockers of L-T/L-N/L-Ca2+ channelsReferencesМоисеев ВС, Мухин НА, Смирнов ВА и др. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Клиническая фармакология и терапия 2014; 23 (3): 4-27Moiseev VS, Mukhin NA, Smirnov AV et al. National recommendations. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Clinical Pharmacology and Therapy. 2014; 23 (3): 4-27. (In Russ.)Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7):1281-1357. doi: 10.1097/01.hjh.0000431740.32696.ccMancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7):1281-1357. doi: 10.1097/01.hjh.0000431740.32696.ccPugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs 2019; 79 (4): 365-379. doi: 10.1007/s40265-019-1064-1Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs 2019; 79 (4): 365-379. doi: 10.1007/s40265-019-1064-1Xie X, Liu Y, Perkovic V et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016; 67 (5): 728-741. doi: 10.1053/j.ajkd.2015.10.011Xie X, Liu Y, Perkovic V et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016; 67 (5): 728-741. doi: 10.1053/j.ajkd.2015.10.011Cheng Y, Huang R, Kim S et al. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2016; 95 (28): e4167. doi: 10.1097/MD.0000000000004167Cheng Y, Huang R, Kim S et al. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2016; 95 (28): e4167. doi: 10.1097/MD.0000000000004167Lu Z, Chen Y, Li L et al. Combination therapy of reninangiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. J Hum Hypertens 2017; 31 (1): 1-13. doi: 10.1038/jhh.2015.125Lu Z, Chen Y, Li L et al. Combination therapy of reninangiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. J Hum Hypertens 2017; 31 (1): 1-13. doi: 10.1038/jhh.2015.125Risoz CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014; 6 (7):517-530. doi: 10.4330/wic.v.6i.7.517Risoz CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014; 6 (7):517-530. doi: 10.4330/wic.v.6i.7.517Grosskopf I, Shaish A, Charach J et al. Nifedipine treatment of hypertension is associated with accelerated clearance of postprandial lipemia. Horm Metab Res 2016; 48 (4): 257-262. doi: 10.1055/s-0035-1565180Grosskopf I, Shaish A, Charach J et al. Nifedipine treatment of hypertension is associated with accelerated clearance of postprandial lipemia. Horm Metab Res 2016; 48 (4): 257-262. doi: 10.1055/s-0035-1565180Huang RS, Cheng YM, Zeng XX et al. Renoprotective effect of the combination of renin-angiotensin system inhibitor and calcium channel blocker in patients with hypertension and chronic kidney disease. Clin Med J (Engl.) 2016; 129 (5): 562-569. doi: 10.4103/0366-6999.176987Huang RS, Cheng YM, Zeng XX et al. Renoprotective effect of the combination of renin-angiotensin system inhibitor and calcium channel blocker in patients with hypertension and chronic kidney disease. Clin Med J (Engl.) 2016; 129 (5): 562-569. doi: 10.4103/0366-6999.176987Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (8): 936-946. doi: 10.1001/archinte.165.8.936Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (8): 936-946. doi: 10.1001/archinte.165.8.936Rahman M, Ford CE, Cutler JA et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012; 7 (6): 989-1002. doi: 10.2215/CJN.07800811Rahman M, Ford CE, Cutler JA et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012; 7 (6): 989-1002. doi: 10.2215/CJN.07800811Esnault VL, Brown EA, Apetrei E et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3 year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008; 30 (3): 482-489. doi: 10.1016/j.clinthera.2008.03.006Esnault VL, Brown EA, Apetrei E et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3 year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008; 30 (3): 482-489. doi: 10.1016/j.clinthera.2008.03.006Narumi H, Takano H, Shindo S et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res 2011; 34 (1): 62-69. doi: 10.1038/hr.2010.186Narumi H, Takano H, Shindo S et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res 2011; 34 (1): 62-69. doi: 10.1038/hr.2010.186Backris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375 (9721): 1173-1181. doi: 10.1016/S0140-6736(09)62100-0Backris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375 (9721): 1173-1181. doi: 10.1016/S0140-6736(09)62100-0Takenaka T, Uchida K, Kojima E et al. Amlodipine and loop diuretics as a second anti-hypertensive medication for the treatment of hypertension with chronic kidney disease. Clin Exp Hypertens 2011; 33 (4): 210-215. doi: 10.3109/10641963.2011.583965Takenaka T, Uchida K, Kojima E et al. Amlodipine and loop diuretics as a second anti-hypertensive medication for the treatment of hypertension with chronic kidney disease. Clin Exp Hypertens 2011; 33 (4): 210-215. doi: 10.3109/10641963.2011.583965Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100 (3): 342-353. doi: 10.1161/01.RES.0000256155.31133.49Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100 (3): 342-353. doi: 10.1161/01.RES.0000256155.31133.49Ott C, Schneider MP, Ralf U et al. Effects of manidipine vs amlodipine on intrarenal haemodynamics in patients with arte rial hypertension. J Clin Pharmacol 2013; 75 (1): 129-135. doi: 10.1111/j.1365-2125.2012.04336.xOtt C, Schneider MP, Ralf U et al. Effects of manidipine vs amlodipine on intrarenal haemodynamics in patients with arte rial hypertension. J Clin Pharmacol 2013; 75 (1): 129-135. doi: 10.1111/j.1365-2125.2012.04336.xHomma K, Hayashi K, Yamaguchi S et al.. Renal microcirculation and calcium channel subtypes. Curr Hypertens Rev 2013; 9 (3): 182-186. doi: 10.2174/1573402110666140131100617Homma K, Hayashi K, Yamaguchi S et al.. Renal microcirculation and calcium channel subtypes. Curr Hypertens Rev 2013; 9 (3): 182-186. doi: 10.2174/1573402110666140131100617Konoshita T, Makino Y, Kimura T et al. A new generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L-type calcium channel blocker. J Hypertens 2010; 28 (10): 2156-2160. doi: 10.1097/HJH.06013e32833d01ddKonoshita T, Makino Y, Kimura T et al. A new generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L-type calcium channel blocker. J Hypertens 2010; 28 (10): 2156-2160. doi: 10.1097/HJH.06013e32833d01ddTawaramoto K, Kaneto H, Hashiramoto M et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr 2015; 17 (7) 80. doi: 10.1186/s13098-015-0073-9Tawaramoto K, Kaneto H, Hashiramoto M et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr 2015; 17 (7) 80. doi: 10.1186/s13098-015-0073-9Friis UG, Jorgensen F, Adreasen D et al. Membrane potential and cation channels in rat juxtaglomerular cells. Acta Physiol Scand 2004; 181 (4): 391-396. doi: 10.1111/j.1365-201X.2004.01310.xFriis UG, Jorgensen F, Adreasen D et al. Membrane potential and cation channels in rat juxtaglomerular cells. Acta Physiol Scand 2004; 181 (4): 391-396. doi: 10.1111/j.1365-201X.2004.01310.xAritomi S, Konda T, Yoshimura M. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart Vessels 2012; 27 (4): 419-423. doi: 10.1007/s00380-011-0191-8Aritomi S, Konda T, Yoshimura M. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart Vessels 2012; 27 (4): 419-423. doi: 10.1007/s00380-011-0191-8Verbeke F, Lindley E, Van Bortel L et al. European Renal Best Practice (EBP) position statement on the kidney disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in nondialysis-dependent chronic kidney disease: an endorsement with caveats for real-life application. Nephrol Dial Transplan 2014; 29 (3): 490-496. doi: 10.1093/ndt/gft321Verbeke F, Lindley E, Van Bortel L et al. European Renal Best Practice (EBP) position statement on the kidney disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in nondialysis-dependent chronic kidney disease: an endorsement with caveats for real-life application. Nephrol Dial Transplan 2014; 29 (3): 490-496. doi: 10.1093/ndt/gft321Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci 2018; 22 (12): 4025-4031. doi: 10.26355/eurrev_201806_15289Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci 2018; 22 (12): 4025-4031. doi: 10.26355/eurrev_201806_15289Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35 (3):775-779. doi: 10.1161/01.HYP.35.3.775Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35 (3):775-779. doi: 10.1161/01.HYP.35.3.775Cominacini L, Fratta-Pasini A, Garbin U et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun 2003; 302 (4): 679-684. doi: 10.1016/S0006-291X(03)00158-XCominacini L, Fratta-Pasini A, Garbin U et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun 2003; 302 (4): 679-684. doi: 10.1016/S0006-291X(03)00158-XVasigar P, Batmanabane M. Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother 2013; 4 (4): 238-242. doi: 10.4103/0976-500X.119707Vasigar P, Batmanabane M. Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother 2013; 4 (4): 238-242. doi: 10.4103/0976-500X.119707Fogari R, Mugellini A, Zoppi A et al. Differential effect of lercanidipine and nifedipine GTTS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-599. doi: 10.1016/S0895-7061(03)00901-4Fogari R, Mugellini A, Zoppi A et al. Differential effect of lercanidipine and nifedipine GTTS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-599. doi: 10.1016/S0895-7061(03)00901-4Seravalle J, Brambilla J, Pizzalla DP et al. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens 2016; 10 (3): 244-251. doi: 10.1016/j.jash/2016.01.006Seravalle J, Brambilla J, Pizzalla DP et al. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens 2016; 10 (3): 244-251. doi: 10.1016/j.jash/2016.01.006Tsiofis K, Tsiofis C, Dimitradis K et al. Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. Curr Med Res Opin 2016; 32 (supl 2): 35-41. doi: 10.1080/03007995.2016.1218839Tsiofis K, Tsiofis C, Dimitradis K et al. Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. Curr Med Res Opin 2016; 32 (supl 2): 35-41. doi: 10.1080/03007995.2016.1218839Dalla-Vestra M, Pozza J, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabetes, ipertensione, albuminuria, lercanidipine). Diabetes Nutr Metab 2004;17 (5):259-266Dalla-Vestra M, Pozza J, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabetes, ipertensione, albuminuria, lercanidipine). Diabetes Nutr Metab 2004;17 (5):259-266Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure. The ZAFRA study. Ren Fail 2005; 27 (1): 73-80. doi: 10.1081/JDI-42801Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure. The ZAFRA study. Ren Fail 2005; 27 (1): 73-80. doi: 10.1081/JDI-42801Robles NR, Romero B, de Vinuesa EG et al.. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32 (2): 192-197. doi: 10.3109/08860220903541135Robles NR, Romero B, de Vinuesa EG et al.. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32 (2): 192-197. doi: 10.3109/08860220903541135Robles NR, Calvo C, Sobrino J et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin 2016; 32 (supl 2): 29-34. doi: 10.1080/03007995.2016.1218838Robles NR, Calvo C, Sobrino J et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin 2016; 32 (supl 2): 29-34. doi: 10.1080/03007995.2016.1218838Кузьмин ОБ, Жежа ВВ, Ландарь ЛН. Нефропротективные свойства дигидропиридиновых блокаторов Са2+ каналов. Обзоры по клинической фармакологии и лекарственной терапии 2010; 8 (1): 6-12Kuz’min OB, Zhezha VV, Landar’ LN. Nephroprotective properties of dihydropyridine Ca2+ cannels blockers. Reviews on Clinical Pharmacology and Drug Therapy 2010; 8 (1): 6-12. (In Russ.)Wu G, Xu M, Xu K, Hu Y. Benedipine protects kidney through inhibiting ROCK1 activity and reducing the epithelial-mesenchymal transdifferentiation in type 1 diabetic rats. J Diabetes Res 2013; 2013: 174526. doi: 10.1155/2013/174526Wu G, Xu M, Xu K, Hu Y. Benedipine protects kidney through inhibiting ROCK1 activity and reducing the epithelial-mesenchymal transdifferentiation in type 1 diabetic rats. J Diabetes Res 2013; 2013: 174526. doi: 10.1155/2013/174526Kazama I, Baba A, Matsubara M et al. Benedipine suppresses in situ proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure. Nephron Exp Nephrol 2014; 128 (1-2): 67-79. doi: 10.1159/000368080Kazama I, Baba A, Matsubara M et al. Benedipine suppresses in situ proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure. Nephron Exp Nephrol 2014; 128 (1-2): 67-79. doi: 10.1159/000368080Akizuki O, Inayoshi A, Kitayama T et al. Blockade of T-type voltage-dependent Ca2+ channels by benedipine, a dihydropyridine channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584 (1-3): 424-434. doi: 10.1016/j.ejphar.2008.02.001Akizuki O, Inayoshi A, Kitayama T et al. Blockade of T-type voltage-dependent Ca2+ channels by benedipine, a dihydropyridine channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584 (1-3): 424-434. doi: 10.1016/j.ejphar.2008.02.001Tsutamoto T, Tanaka T, Yamaji M et al. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 2009; 32 (8): 670-674. doi: 10.1038/hr.2009.78Tsutamoto T, Tanaka T, Yamaji M et al. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 2009; 32 (8): 670-674. doi: 10.1038/hr.2009.78Abe M, Okada K, Maruyama N et al. Benedipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34 (2): 268-273. doi: 10.1038/hr.2010.221Abe M, Okada K, Maruyama N et al. Benedipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34 (2): 268-273. doi: 10.1038/hr.2010.221Ohishi M, Takagi T, Ito N et al. Renal-protective effect of T- and L-type channel blockers in hypertensive patients: an amlodipine-to-benedipine changeover (ABC) study. Hypertens Res 2007; 30 (9): 797-806. doi: 10.1291/hypres.30.797Ohishi M, Takagi T, Ito N et al. Renal-protective effect of T- and L-type channel blockers in hypertensive patients: an amlodipine-to-benedipine changeover (ABC) study. Hypertens Res 2007; 30 (9): 797-806. doi: 10.1291/hypres.30.797Abe M, Okada K, Maruyama T et al. Comparison of the antiproteinuric effects of the calcium channel blockers benedipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32 (4): 270-275.doi: 10.1038/hr.2009.11Abe M, Okada K, Maruyama T et al. Comparison of the antiproteinuric effects of the calcium channel blockers benedipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32 (4): 270-275.doi: 10.1038/hr.2009.11Tani S, Takahashi A, Nagao K, Hirayama A. Effect of T/Ltype calcium channel blocker benedipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benedipine. Int Heart J 2014; 55 (6): 519-525. doi: 10.1536/ihj.14-034Tani S, Takahashi A, Nagao K, Hirayama A. Effect of T/Ltype calcium channel blocker benedipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benedipine. Int Heart J 2014; 55 (6): 519-525. doi: 10.1536/ihj.14-034Takayama T, Yoda S, Yjima Y et al. Improvement of augmentation index and urinary albumin excretion with benedipine in hypertensive patients with chronic kidney disease. Int Heart J 2016; 57 (1): 53-60. doi: 10.1536/ihj.15-208Takayama T, Yoda S, Yjima Y et al. Improvement of augmentation index and urinary albumin excretion with benedipine in hypertensive patients with chronic kidney disease. Int Heart J 2016; 57 (1): 53-60. doi: 10.1536/ihj.15-208Hishikawa K, Takase O, Idei M, Fujito T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76 (2) :230-231. doi: 10.1038/ki.2009.146Hishikawa K, Takase O, Idei M, Fujito T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76 (2) :230-231. doi: 10.1038/ki.2009.146Hayashi M, Yamaji Y, Nakazato Y, Saruta T. The effect of calcium channel blockers on nuclear factor kappa B activation in the mesangial cells. Hypertens Res 2000; 23 (5): 521-525Hayashi M, Yamaji Y, Nakazato Y, Saruta T. The effect of calcium channel blockers on nuclear factor kappa B activation in the mesangial cells. Hypertens Res 2000; 23 (5): 521-525Lei B, Nakano D, Fujisawa T et al. N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. J Parmacol Sci 2012; 119 (4): 359-367. doi: 10.1254/jphs.12075FPLei B, Nakano D, Fujisawa T et al. N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. J Parmacol Sci 2012; 119 (4): 359-367. doi: 10.1254/jphs.12075FPMishima K, Maeshima A, Miya M et al. Involvement of N-type Ca (2+) channels in the fibrotic process of the kidney in the rats. Am J Physiol Renal Physiol 2013; 304 (6): F665-673. doi: 10.1152/ajprenal.00561.2012Mishima K, Maeshima A, Miya M et al. Involvement of N-type Ca (2+) channels in the fibrotic process of the kidney in the rats. Am J Physiol Renal Physiol 2013; 304 (6): F665-673. doi: 10.1152/ajprenal.00561.2012Mori Y, Aritomi S, Niinuma K et al. Additive effects of cilnidipine, an L/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima fatty rats with type 2 diabetes mellitus. Drug Des Devel Ther 2014; 8: 799-810. doi: 10.2147/DDDT.S47441Mori Y, Aritomi S, Niinuma K et al. Additive effects of cilnidipine, an L/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima fatty rats with type 2 diabetes mellitus. Drug Des Devel Ther 2014; 8: 799-810. doi: 10.2147/DDDT.S47441Uhrenholt TR, Nederquard O. Calcium channels involved in noradrenaline release from sympathetic neurons in rabbit carotid artery. Pharmacol Toxicol 2003; 92 (5): 226-233. doi: 10.1034/j.1600-0773.2003.920505Uhrenholt TR, Nederquard O. Calcium channels involved in noradrenaline release from sympathetic neurons in rabbit carotid artery. Pharmacol Toxicol 2003; 92 (5): 226-233. doi: 10.1034/j.1600-0773.2003.920505Toba H, Yoshida M, Tojo C et al. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in desoxycorticosterone acetate-salt hypertensive rats. Hypertens Res 2011; 34 (4): 521-529. doi: 10.1038/hr.2010.279Toba H, Yoshida M, Tojo C et al. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in desoxycorticosterone acetate-salt hypertensive rats. Hypertens Res 2011; 34 (4): 521-529. doi: 10.1038/hr.2010.279Aritomi S, Wagatsuma H, Humata T et al. Expression of N-type calcium channels human adrenocortical cells and their contribution to corticosteroid synthesis. Hypertens Res 2011; 34 (2): 193-201. doi: 10.1038/hr.2010.191Aritomi S, Wagatsuma H, Humata T et al. Expression of N-type calcium channels human adrenocortical cells and their contribution to corticosteroid synthesis. Hypertens Res 2011; 34 (2): 193-201. doi: 10.1038/hr.2010.191Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009; 27 (2): 124-139. doi: 10.1111/j.1755-5922.2009.00079.xTakahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009; 27 (2): 124-139. doi: 10.1111/j.1755-5922.2009.00079.xSoeki T, Kitani M, Kusunose K et al. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res 2012; 35 (11): 1058-1062. doi: 10.1038/hr.2012.96Soeki T, Kitani M, Kusunose K et al. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res 2012; 35 (11): 1058-1062. doi: 10.1038/hr.2012.96Uchida S, Takahashi M, Sugawara M et al. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). J Clin Hypertens (Greenwich) 2014; 16 (10): 746-753. doi: 10.1111/jch.12412Uchida S, Takahashi M, Sugawara M et al. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). J Clin Hypertens (Greenwich) 2014; 16 (10): 746-753. doi: 10.1111/jch.12412Singh VK, Mishra A, Gupta KK et al. Reduction of microalbuminuria in type 2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine. Indian J Nephrol 2015; 25 (6): 334-339. doi: 10.4103/0971-4065.151764Singh VK, Mishra A, Gupta KK et al. Reduction of microalbuminuria in type 2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine. Indian J Nephrol 2015; 25 (6): 334-339. doi: 10.4103/0971-4065.151764Konoshita T, Kaeriyama S, Urabe M et al. On the top of ARB N/L-type calcium channel blocker leads to less elevation of aldosterone. Biosci Rep 2016; 36 (5): e00381. doi: 10.1042/BSR20160129Konoshita T, Kaeriyama S, Urabe M et al. On the top of ARB N/L-type calcium channel blocker leads to less elevation of aldosterone. Biosci Rep 2016; 36 (5): e00381. doi: 10.1042/BSR20160129Zhao PL, Wang XT, Zhang XM et al. Tubular and cellular localization of the cardiac L-type calcium channel in the rat kidney. Kidney Int 2002: 61 (4): 1398-1406. doi: 10.1046/j.1523-1755.2002.00267.xZhao PL, Wang XT, Zhang XM et al. Tubular and cellular localization of the cardiac L-type calcium channel in the rat kidney. Kidney Int 2002: 61 (4): 1398-1406. doi: 10.1046/j.1523-1755.2002.00267.xAndreasen D, Jensen BL, Hansen PB et al. The alpha (1G)-subunits of voltage-dependent Ca (2+) channel is localized in rat distal nephron and collecting duct. Am J Physiol Renal Physiol 2000; 279 (6): F997-F1005Andreasen D, Jensen BL, Hansen PB et al. The alpha (1G)-subunits of voltage-dependent Ca (2+) channel is localized in rat distal nephron and collecting duct. Am J Physiol Renal Physiol 2000; 279 (6): F997-F1005Xue C, Zhou C, Yang B et al. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopriltreated hypertensive patients with chronic kidney disease: protocol for a randomized controlled trial. BMJ Open 2017; 7 (2): e013672. doi: 10.1136/bmjopen-2016-013672Xue C, Zhou C, Yang B et al. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopriltreated hypertensive patients with chronic kidney disease: protocol for a randomized controlled trial. BMJ Open 2017; 7 (2): e013672. doi: 10.1136/bmjopen-2016-013672

The authors declare that there are no conflicts of interest present.